NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Unity Biotechnology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.43 +0.71 (+6.06 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$11.53Now: $12.43▼$12.4650-Day Range$7.60MA: $9.08▼$11.9852-Week Range$4.62Now: $12.43▼$15.44Volume686,028 shsAverage Volume353,480 shsMarket Capitalization$646.86 millionP/E RatioN/ADividend YieldN/ABeta0.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.25, Unity Biotechnology has a potential upside of 103.1% from its current price of $12.43.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesUnity Biotechnology has received 131 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUnity Biotechnology has received 124 “underperform” votes. (Add your “underperform” vote.)Community SentimentUnity Biotechnology has received 51.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 33.60% of the stock of Unity Biotechnology is held by insiders.Percentage Held by Institutions44.56% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to grow in the coming year, from ($1.95) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UBX Previous Symbol CUSIPN/A CIK1463361 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees94 Outstanding Shares52,040,000Market Cap$646.86 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $12.43 +0.71 (+6.06 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive UBX News and Ratings via Email Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)? Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, UBX shares have increased by 130.6% and is now trading at $12.43. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Unity Biotechnology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology. When is Unity Biotechnology's next earnings date? Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Unity Biotechnology. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology Inc (NASDAQ:UBX) released its earnings results on Friday, July, 31st. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.13. View Unity Biotechnology's earnings history. What price target have analysts set for UBX? 4 brokerages have issued 1-year price targets for Unity Biotechnology's stock. Their forecasts range from $13.00 to $35.00. On average, they anticipate Unity Biotechnology's stock price to reach $25.25 in the next year. This suggests a possible upside of 103.1% from the stock's current price. View analysts' price targets for Unity Biotechnology. Has Unity Biotechnology been receiving favorable news coverage? News headlines about UBX stock have been trending somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Unity Biotechnology earned a coverage optimism score of 0.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Unity Biotechnology. Who are some of Unity Biotechnology's key competitors? Some companies that are related to Unity Biotechnology include Taro Pharmaceutical Industries (TARO), LivaNova (LIVN), Cantel Medical (CMD), Inovio Pharmaceuticals (INO), Option Care Health (OPCH), STAAR Surgical (STAA), Immunovant (IMVT), Genus (GNS), Karuna Therapeutics (KRTX), ProShares UltraShort DJ-UBS Commodity (CMD), Turning Point Therapeutics (TPTX), Legend Biotech (BNR), Integer (ITGR), Kodiak Sciences (KOD) and Nanosonics (NAN). View all competitors. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NVIDIA (NVDA), NIO (NIO), Advanced Micro Devices (AMD), Canopy Growth (CGC), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), Inseego (INSG), Square (SQ), AbbVie (ABBV) and Enphase Energy (ENPH). Who are Unity Biotechnology's key executives? Unity Biotechnology's management team includes the following people: Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)Dr. Anirvan Ghosh, Director & CEO (Age 56)Dr. Jan M. van Deursen, FounderDr. Judith Campisi, Founder When did Unity Biotechnology IPO? (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. What is Unity Biotechnology's stock symbol? Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX." Who are Unity Biotechnology's major shareholders? Unity Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (11.72%), Russell Investments Group Ltd. (0.42%), Asymmetry Capital Management L.P. (0.23%), Bessemer Group Inc. (0.20%), Bank of New York Mellon Corp (0.17%) and California Public Employees Retirement System (0.13%). Which institutional investors are selling Unity Biotechnology stock? UBX stock was sold by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, UBS Group AG, Russell Investments Group Ltd., Investors Financial Group LLC, and Goldman Sachs Group Inc.. Which institutional investors are buying Unity Biotechnology stock? UBX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Asymmetry Capital Management L.P., Bessemer Group Inc., California Public Employees Retirement System, Bank of America Corp DE, SG Americas Securities LLC, Fort Point Capital Partners LLC, and ProShare Advisors LLC. How do I buy shares of Unity Biotechnology? Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Unity Biotechnology's stock price today? One share of UBX stock can currently be purchased for approximately $12.43. How big of a company is Unity Biotechnology? Unity Biotechnology has a market capitalization of $646.86 million. Unity Biotechnology employs 94 workers across the globe. This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
